SECUKINUMAB DEMONSTRATES LOW RADIOGRAPHIC PROGRESSION AND SUSTAINED EFFICACY THROUGH 4 YEARS IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS

被引:6
作者
Baraliakos, X. [1 ,2 ]
Braun, J. [1 ,2 ]
Deodhar, A. [3 ]
Poddubny, D. [4 ]
Emery, P. [5 ]
Delicha, E. M. [6 ]
Talloczy, Z. [7 ]
Porter, B. [8 ]
机构
[1] Rheumazentrum Ruhrgebiet, Herne, Germany
[2] Ruhr Univ, Bochum, Germany
[3] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[4] Charite Univ Med Berlin, Berlin, Germany
[5] Univ Leeds, Leeds, W Yorkshire, England
[6] Novartis Pharma AG, Basel, Switzerland
[7] Novarlis Pharmaceut Corp, E Hanover, NJ USA
[8] Novarlis Pharmaceut Corp, E Hanover, NJ USA
关键词
D O I
10.1136/annrheumdis-2018-eular.1396
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
SAT0268
引用
收藏
页码:997 / 998
页数:2
相关论文
共 1 条
  • [1] Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study
    Braun, Juergen
    Baraliakos, Xenofon
    Deodhar, Atul
    Baeten, Dominique
    Sieper, Joachim
    Emery, Paul
    Readie, Aimee
    Martin, Ruvie
    Mpofu, Shephard
    Richards, Hanno B.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (06) : 1070 - 1077